Brief Report - (2025) Volume 9, Issue 4
Received: 01-Aug-2025, Manuscript No. jid-26-187000;
Editor assigned: 04-Aug-2025, Pre QC No. P-187000;
Reviewed: 18-Aug-2025, QC No. Q-187000;
Revised: 22-Aug-2025, Manuscript No. R-187000;
Published:
29-Aug-2025
, DOI: 10.37421/2684-4559.2025.9.334
Citation: Petrova, Elena. "Chronic Hepatitis E in Transplant Recipients: Management and Outcomes." Clin Infect Dis 13 (2025):335.
Copyright: © 2025 Petrova E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Chronic hepatitis E virus (HEV) infection in solid organ transplant recipients (HTR) presents a significant clinical challenge due to its tendency to become chronic and its potential to compromise graft function or lead to failure. The immunopathogenesis of this condition is intricate, involving a complex interaction between the host's immune system and the HEV, especially under conditions of immunosuppression. Factors such as the intensity of immunosuppression, the specific immunosuppressive agents employed, and individual genetic predispositions can all influence the body's ability to clear the virus and the subsequent development of chronic infection. A thorough understanding of these immune dysregulations is paramount for the development of targeted therapeutic strategies aimed at managing HEV in HTR.[1]
The compromised immune surveillance characteristic of transplant recipients, particularly the suppression of T cell responses, plays a crucial role in driving HEV chronicity. A robust T cell-mediated immunity is recognized as essential for viral clearance. However, immunosuppressive drugs can dampen this response, thereby facilitating HEV persistence. Emerging research is beginning to shed light on the specific immune cell populations and cytokine profiles associated with chronic HEV infection in this vulnerable demographic, paving the way for novel immunomodulatory therapies.[2] It is evident that different immunosuppressive regimens can have varying impacts on the risk of HEV chronicity. For instance, calcineurin inhibitors and purine synthesis inhibitors, which are commonly utilized in transplant settings, can significantly affect T-cell and B-cell functions, respectively, potentially hindering effective viral control. Identifying which specific agents are most strongly linked to adverse HEV outcomes is therefore vital for optimizing immunosuppression strategies in transplant candidates and recipients who are seropositive for HEV.[3] The specific genotype of the HEV also plays a role in its pathogenic potential and the resulting immune response. In developed countries, including among transplant recipients, genotype 3 is the most frequently implicated cause of chronic HEV infection. Investigating the distinct immune evasion mechanisms employed by different HEV genotypes could offer valuable insights for the development of genotype-specific treatments or vaccines.[4] A serious complication of chronic HEV in HTR is the development of fibrosis and cirrhosis. This liver damage is driven by a sustained inflammatory response and persistent viral replication. Consequently, early detection and prompt management are critical to prevent the progression of liver disease to a decompensated state and to mitigate the potential need for re-transplantation.[5] The diagnostic landscape for chronic HEV in HTR is marked by challenges, particularly in the interpretation of serological markers and the necessity for molecular detection methods. While anti-HEV IgM antibodies may be transient or entirely absent, a sustained high avidity IgG response, coupled with detectable HEV RNA in serum or stool, is generally indicative of chronic infection. Regular monitoring for HEV RNA in HTR at high risk is therefore considered essential.[6] Treatment strategies for chronic HEV in HTR primarily focus on reducing the level of immunosuppression and, when deemed necessary, administering antiviral agents such as ribavirin. However, the response to ribavirin can be highly variable, and its long-term safety profile in transplant recipients necessitates careful consideration. Determining the optimal duration and management protocols for treatment remains an active area of research.[7] The role of genetic factors in an individual's susceptibility to chronic HEV in HTR is an area of growing investigation. Certain human leukocyte antigen (HLA) types or polymorphisms within immune response genes may predispose individuals to a less effective antiviral response, thereby leading to persistent infection. Further studies are indispensable to identify these critical genetic markers.[8] While rare, hepatitis E virus-induced hepatocellular carcinoma (HCC) has been documented in immunocompromised individuals, including transplant recipients with chronic HEV infection. The persistent inflammation and potential direct oncogenic effects of HEV may contribute to the development of HCC. Consequently, long-term surveillance for HCC in HTR with chronic HEV is strongly warranted.[9] Effectively managing HEV in HTR demands a multidisciplinary approach, integrating the expertise of infectious disease specialists, hepatologists, and transplant surgeons. Key strategies encompass HEV screening in both donor and recipient populations, meticulous optimization of immunosuppression, prompt and accurate diagnosis, and the implementation of effective treatment to avert graft loss and enhance patient survival.[10]Chronic hepatitis E virus (HEV) infection in transplant recipients (HTR) represents a significant clinical hurdle, characterized by its propensity for chronicity and the potential to induce graft dysfunction or failure. The immunopathogenesis is multifaceted, arising from a complex interplay between the host immune system and the HEV, particularly within the context of immunosuppression. Key factors influencing viral clearance and the development of chronic infection include the degree of immunosuppression, the specific immunosuppressive agents used, and individual genetic makeup. Understanding these immune dysregulations is crucial for designing targeted therapeutic strategies for HEV management in HTR.[1]
The diminished immune surveillance in transplant recipients, especially the suppression of T cell responses, is a primary driver of HEV chronicity. A robust T cell-mediated immunity is vital for viral clearance, but immunosuppressive drugs can attenuate this response, allowing HEV to persist. Ongoing research is progressively elucidating the specific immune cell populations and cytokine profiles associated with chronic HEV infection in this vulnerable group, thereby paving the way for the development of novel immunomodulatory therapies.[2] Different immunosuppressive regimens have been observed to differentially influence the risk of HEV chronicity. Commonly used agents in transplant settings, such as calcineurin inhibitors and purine synthesis inhibitors, can profoundly impact T-cell and B-cell functions, respectively, potentially compromising viral control. Identifying the agents most strongly associated with adverse HEV outcomes is essential for optimizing immunosuppression strategies in HEV-seropositive transplant candidates and recipients.[3] The genotype of the HEV is another factor that contributes to its pathogenic potential and the host's immune response. Genotype 3 is predominantly responsible for chronic HEV infections in developed countries, including among transplant recipients. A deeper understanding of the specific immune evasion mechanisms employed by different HEV genotypes could inform the development of genotype-specific treatments or vaccines.[4] The progression to fibrosis and cirrhosis is a serious complication of chronic HEV in HTR. This occurs due to the sustained inflammatory response and continuous viral replication, which collectively contribute to liver damage. Therefore, early detection and timely management are critical to prevent the disease from progressing to decompensated liver disease and to avoid the necessity of re-transplantation.[5] Diagnostic challenges in chronic HEV in HTR include difficulties in interpreting serological results and the crucial need for molecular detection. While anti-HEV IgM antibodies may be transient or absent, a persistent high avidity IgG response along with detectable HEV RNA in serum or stool typically indicates chronic infection. Consequently, regular monitoring of HEV RNA is essential for high-risk HTR.[6] Therapeutic strategies for chronic HEV in HTR primarily involve reducing the intensity of immunosuppression and, when indicated, employing antiviral agents like ribavirin. The efficacy of ribavirin can vary, and its long-term safety in transplant recipients requires careful monitoring. Research is ongoing to determine the optimal treatment duration and management protocols.[7] Genetic factors are increasingly recognized as playing a role in susceptibility to chronic HEV in HTR. Certain human leukocyte antigen (HLA) types or polymorphisms in immune response genes might predispose individuals to a less effective antiviral response, leading to persistent infection. Further research is necessary to identify these specific genetic markers.[8] Hepatitis E virus-induced hepatocellular carcinoma (HCC) is a rare but reported complication in immunocompromised individuals, including transplant recipients with chronic HEV. The chronic inflammation and potential direct oncogenic effects of HEV may contribute to HCC development. Therefore, long-term surveillance for HCC in HTR with chronic HEV is recommended.[9] The effective management of HEV in HTR necessitates a multidisciplinary approach involving infectious disease specialists, hepatologists, and transplant surgeons. This includes HEV screening of donors and recipients, careful optimization of immunosuppression, prompt diagnosis, and appropriate treatment to prevent graft loss and improve patient survival.[10]Chronic hepatitis E virus (HEV) infection in solid organ transplant recipients (HTR) is a significant clinical issue due to its chronicity and potential for graft failure. The pathogenesis involves complex immune dysregulation, with immunosuppression playing a key role in viral persistence. Factors like immunosuppressive agents and HEV genotype influence outcomes. Complications include fibrosis, cirrhosis, and rarely, hepatocellular carcinoma. Diagnosis requires careful interpretation of serology and molecular testing. Management focuses on reducing immunosuppression and antiviral therapy, with a multidisciplinary approach being crucial for preventing graft loss and improving survival.
Clinical Infectious Diseases: Open Access received 1149 citations as per Google Scholar report
